Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'RXi Pharmaceuticals Corporation - Product Pipeline Review - 2016', provides an overview of the RXi Pharmaceuticals Corporation's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by RXi Pharmaceuticals Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of RXi Pharmaceuticals Corporation - The report provides overview of RXi Pharmaceuticals Corporation including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses RXi Pharmaceuticals Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features RXi Pharmaceuticals Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate RXi Pharmaceuticals Corporation's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for RXi Pharmaceuticals Corporation - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding RXi Pharmaceuticals Corporation's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 RXi Pharmaceuticals Corporation Snapshot 6 RXi Pharmaceuticals Corporation Overview 6 Key Information 6 Key Facts 6 RXi Pharmaceuticals Corporation - Research and Development Overview 7 Key Therapeutic Areas 7 RXi Pharmaceuticals Corporation - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 RXi Pharmaceuticals Corporation - Pipeline Products Glance 12 RXi Pharmaceuticals Corporation - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 RXi Pharmaceuticals Corporation - Early Stage Pipeline Products 14 IND/CTA Filed Products/Combination Treatment Modalities 14 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 RXi Pharmaceuticals Corporation - Drug Profiles 17 diphencyprone 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 RXI-109 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 RNAi Oligonucleotide to Inhibit CTGF for PVR 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 RNAi Oligonucleotide Inhibiting MDM2 for Retinoblastoma 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 RNAi Oligonucleotide to Inhibit SOD-1 for ALS 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 RNAi Oligonucleotide to Inhibit VEGF for Macular Degeneration 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 RXI-209 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 bevasiranib sodium 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 MMP-26051 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 MMP-26052 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 RNAi Oligonucleotide to Inhibit Angiopoietin-2 for Retinal Disease and Cancer 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Cancer 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 RNAi Oligonucleotides to Inhibit Complement C3 for Ophthalmology 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 RNAi Oligonucleotides to Inhibit TNF-alpha for Autoimmune Disorders 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 TRY-26071 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 TRY-26077 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 RXi Pharmaceuticals Corporation - Pipeline Analysis 37 RXi Pharmaceuticals Corporation - Pipeline Products by Target 37 RXi Pharmaceuticals Corporation - Pipeline Products by Route of Administration 39 RXi Pharmaceuticals Corporation - Pipeline Products by Molecule Type 40 RXi Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action 41 RXi Pharmaceuticals Corporation - Recent Pipeline Updates 43 RXi Pharmaceuticals Corporation - Dormant Projects 51 RXi Pharmaceuticals Corporation - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 bevasiranib sodium 52 RXi Pharmaceuticals Corporation - Locations And Subsidiaries 53 Head Office 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
RXi Pharmaceuticals Corporation, Key Information 6 RXi Pharmaceuticals Corporation, Key Facts 6 RXi Pharmaceuticals Corporation - Pipeline by Indication, 2016 8 RXi Pharmaceuticals Corporation - Pipeline by Stage of Development, 2016 10 RXi Pharmaceuticals Corporation - Monotherapy Products in Pipeline, 2016 11 RXi Pharmaceuticals Corporation - Phase II, 2016 12 RXi Pharmaceuticals Corporation - Phase I, 2016 13 RXi Pharmaceuticals Corporation - IND/CTA Filed, 2016 14 RXi Pharmaceuticals Corporation - Preclinical, 2016 15 RXi Pharmaceuticals Corporation - Discovery, 2016 16 RXi Pharmaceuticals Corporation - Pipeline by Target, 2016 37 RXi Pharmaceuticals Corporation - Pipeline by Route of Administration, 2016 39 RXi Pharmaceuticals Corporation - Pipeline by Molecule Type, 2016 40 RXi Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action, 2016 41 RXi Pharmaceuticals Corporation - Recent Pipeline Updates, 2016 43 RXi Pharmaceuticals Corporation - Dormant Developmental Projects,2016 51 RXi Pharmaceuticals Corporation - Discontinued Pipeline Products, 2016 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
